SCHEMBL6080169

SCHEMBL6080169

COC(=O)c1cc(O)c2cc(Br)cc(OC)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
CYP1A2 P05177 1/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
NQO2 P16083 4/20 0.38
LCK P06239 1/20 0.38
GPR35 Q9HC97 1/20 0.38
ERN1 O75460 1/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
TP53 P04637 1/20 0.36
PIM1 P11309 1/20 0.36
KDM4E B2RXH2 2/20 0.35
MAPK1 P28482 1/20 0.35
APP P05067 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6590987 0.87 GPR35 (0.51) L3MBTL1NQO2LCKGPR35ERN1
SCHEMBL6080115 0.87 MAPT (0.40) MAPTGAACYP1A2RECQLL3MBTL1
SCHEMBL6080299 0.84 CNR2 (0.42) MAPTGAARECQLNQO2LCK
SCHEMBL6079733 0.83 NQO2 (0.43) MAPTGAACYP1A2RECQLL3MBTL1
SCHEMBL6081153 0.83 NQO2 (0.41) MAPTGAANQO2LCKGPR35
SCHEMBL6080304 0.83 LCK (0.38) MAPTGAACYP1A2RECQLNQO2
SCHEMBL6080867 0.81 ALDH1A1 (0.43) MAPTGAACYP1A2NQO2LCK
SCHEMBL6080510 0.81 LMNA (0.47) MAPTCYP1A2TP53HSD17B10ALDH1A1
SCHEMBL6080128 0.80 GAA (0.39) MAPTGAACYP1A2RECQLL3MBTL1
SCHEMBL561388 0.80 RXFP1 (0.40) MAPTGAACYP1A2RECQLL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL MAPT 1575/4885GAA 589/4885CYP1A2 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.